IP Library Granted Patent US 41,007
Granted Patent E1
US 41,007 · App. 11/801,428 · Granted Nov 24, 2009

Method for diagnosing selected adenocarcinomas

Assignee: University of South Florida
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 41,007
App. No.
11/801,428
Granted
Nov 24, 2009
Kind
E1
Abstract

A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the, bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.

Claims (2)

1. A protein encoded by the nucleic acid molecule having the sequence shown in SEQ. ID NO. 1.

2. An isolated endometrial bleeding associated factor protein encoded by the nucleic acid sequence shown in SEQ. ID No. 1.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 9, 2011
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026719/0231 →
Continuity (4)
Reissue 0952683300 · Mar 16, 2000
Division 0934281900 · Jun 29, 1999
Continuation 0891942100 · Aug 27, 1997
Provisional Application 6002580000 · Aug 27, 1996